Search Within

Department of Medicine

Formats
  1. Journal Article (19593)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (610)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22321)
  2. Hematologic Malignancies, Division of (13278)
  3. Center for Hematologic Malignancies (11061)
  4. GSK Faculty (10646)
  5. Survivorship Research (9330)
  6. Division of Subspecialty Medicine (7535)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1071)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2111)

More Publishers

Results (39622)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: Primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
    Meeting Abstract

    Banerjee, S.; Aghajanian, C.; Van Nieuwenhuysen, E.; Santin, A.; Ring, K.; Colombo, N.; Thaker, P.; Prendergast, E.; Moore, K.; Chon, H. S.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Characterising the contribution of rare protein-coding variants to prostate cancer risk and severity in 36,866 cases
    Meeting Abstract

    Mitchell, J.; Camacho, N.; Shea, P. R.; Stopsack, K.; Joseph, V.; Burren, O.; Penney, K.; Berchuck, J.; Wang, Q. L.; Goldstein, D.; more...
    European Journal of Human Genetics (2024)

    Fulltext@MSK | Save
  • GVHD therapy with ruxolitinib is frequently associated with cytopenias, but significant decline in hemoglobin level was only observed in non-responders at day 28
    Meeting Abstract

    Gergoudis, S.; Devlin, S. M.; Susman, P.; Singh, A.; Chinapen, S.; Perales, M. A.; Ponce, D. M.
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of budesonide monotherapy for low grade GI GVHD after post transplant cyclophosphamide
    Meeting Abstract

    Cook, M.; Vadakkel, G.; Chinapen, S.; Perales, M. A.; Tamari, R.; Papadopoulos, E. B.; Ponce, D. M.; Shaffer, B. C.; Lin, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Teo, M. Y.; Bajorin, D.; Kotecha, R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Dietary sucrose exacerbates antibiotic-induced microbiome injury in allo-HCT
    Meeting Abstract

    Rangesa, M.; Dai, A.; Adintori, P.; Jogia, W.; Fei, T.; Waters, N.; Baichoo, M.; Ballweg, A.; Sahu, S.; Schluter, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
    Meeting Abstract

    Apolo, A. B.; Ballman, K.; Sonpavde, G. P.; Berg, S.; Kim, W.; Parikh, R.; Teo, M. Y.; Sweis, R. F.; Geynisman, D.; Grivas, P.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Maroto Rey, J. P.; Vulsteke, C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2- expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
    Meeting Abstract

    Galsky, M. D.; Koshkin, V. S.; Campbell, M. T.; Drakaki, A.; Bowman, I.; Rose, A. A. N.; Brown, J. R.; Aragon-Ching, J. B.; Gadde, S.; Harandi, A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save